Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]

View source ↗

Summary

Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were posted in December 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Zandelisib (zandelisib)

Snippet

Sponsor: MEI Pharma, Inc. | Conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2023-12-13